Novartis Fights Enhanced Damages Bid After $178M Jury Loss
Novartis says that it shouldn't have to pay enhanced damages after a jury hit the company with a $177.8 million verdict for selling a skin cancer drug that infringes two patents...To view the full article, register now.
Already a subscriber? Click here to view full article